Multimodal imaging is a useful tool in diagnosing and managing age-related macular degeneration (AMD), according to Julie Rodman, OD, MS, FAAO.
Julie Rodman, OD, MS, FAAO, a professor in the Nova Southeastern University College of Optometry, discussed how multimodal imaging can be used in the management of age-related macular degeneration (AMD) ahead of her session on the topic to be held at the Southeastern Educational Congress of Optometry (SECO) 2025 meeting on Sunday, March 2.
This transcript has been lightly edited for clarity; captions were auto-generated.
Transcript
How can multimodal imaging be used to manage AMD?
Multimodal imaging essentially means either you're using OCT [optical coherence tomography], OCT angiography (OCT-A), fundus autofluorescence, fluorescent angiography—any test that's not just your basic, routine exam. We know, especially now with these new advances in geographic atrophy, that a lot of early disease findings are missed just based on clinical exam. OCT, OCT-A, [and] fundus autofluorescence do an amazing job, each of them in a different way, at identifying high-risk characteristics for both conversion to more advanced stages of disease and also just identification of the disease.
I would argue that any patient that has a wide-field imaging device, like an Optos, a Clarus, an Eidon, they probably have fundus autofluorescence on their camera. They should be getting not only color fundus photography, but also FAF [fundus autofluorescence] on every patient, because that provides that extra insight, or that extra sneak peek into what might be happening that we might not be seeing. It plays a huge role in providing ancillary information to a doctor. I hope that everybody that's practicing medical, optometry, retina, whatever it is, is using these devices in one way or another to supplement their exam.
GLP-1 Receptor Agonists Reduce Adverse Cardiovascular Outcomes, Improve Survival
August 2nd 2025Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival in those with coronary plaque and after ST-elevation myocardial infarction.
Read More
AI, GLP-1s Among Topics to Be Discussed During ASPC Annual Meeting
July 28th 2025The American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease Prevention features multiple sessions on different methods of treating and preventing cardiovascular disease, including through the use of artificial intelligence (AI) and glucagon-like peptide-1 (GLP-1) receptor agonists.
Read More